GLP-1 receptor agonists (GLP-1RAs) increase GLP-1 levels by 10 times or more and exert several pharmacological actions, including appetite-suppressant effects and delayed gastric emptying
Because GLP-2 acts through subepithelial myofibroblasts, which are the same cell population implicated in intestinal fibrogenesis, the risk-benefit profile of GLP-2 agonism may differ substantially between mucosal UC, inflammatory ileal CD, and stricturing or penetrating CD phenotypes, and this phenotypic stratification should be a required feature of future trial design
Pivotal role of leptin-hypothalamus signaling in the etiology of diabetes uncovered by gene therapy: a new therapeutic intervention
If youre concerned about digestive side effects or have a history of gastrointestinal issues, discuss these with your doctor before starting treatment
We understand that the intersection of pharmaceutical and legal matters can be complex and confusing
Total revenues through the third quarter were $277.2 billion, according to the report
